-
Je něco špatně v tomto záznamu ?
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
I. Roos, E. Leray, F. Frascoli, R. Casey, JWL. Brown, D. Horakova, EK. Havrdova, M. Trojano, F. Patti, G. Izquierdo, S. Eichau, M. Onofrj, A. Lugaresi, A. Prat, M. Girard, P. Grammond, P. Sola, D. Ferraro, S. Ozakbas, R. Bergamaschi, MJ. Sá, E....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
32947619
DOI
10.1093/brain/awaa231
Knihovny.cz E-zdroje
- MeSH
- časové faktory MeSH
- dospělí MeSH
- imunologické faktory aplikace a dávkování MeSH
- imunosupresiva aplikace a dávkování MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- natalizumab aplikace a dávkování MeSH
- progrese nemoci * MeSH
- prospektivní studie MeSH
- registrace MeSH
- roztroušená skleróza diagnostické zobrazování farmakoterapie patofyziologie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments ('therapeutic lag') on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and yearly review were included in the analysis. For analysis of disability progression, all events in the subsequent 5-year period were included. Density curves, representing incidence of relapses and 6-month confirmed progression events, were separately constructed for each sufficiently represented therapy. Monte Carlo simulations were performed to identify the first local minimum of the first derivative after treatment start; this point represented the point of stabilization of treatment effect, after the maximum treatment effect was observed. The method was developed in a discovery cohort (MSBase), and externally validated in a separate, non-overlapping cohort (OFSEP). A merged MSBase-OFSEP cohort was used for all subsequent analyses. Annualized relapse rates were compared in the time before treatment start and after the stabilization of treatment effect following commencement of each therapy. We identified 11 180 eligible treatment epochs for analysis of relapses and 4088 treatment epochs for disability progression. External validation was performed in four therapies, with no significant difference in the bootstrapped mean differences in therapeutic lag duration between registries. The duration of therapeutic lag for relapses was calculated for 10 therapies and ranged between 12 and 30 weeks. The duration of therapeutic lag for disability progression was calculated for seven therapies and ranged between 30 and 70 weeks. Significant differences in the pre- versus post-treatment annualized relapse rate were present for all therapies apart from intramuscular interferon beta-1a. In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progression in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience early on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag.
Central Clinical School Monash University Melbourne 3004 Australia
Centro Hospitalar Universitário de São João and Universidade Fernando Pessoa 4249 004 Porto Portugal
CHUM MS Center and Universite de Montreal Montreal H2L 4M1 Canada
CISSS Chaudière Appalache Lévis Levis G6X 0A1 Canada
Cliniques universitaires Saint Luc Brussels 1200 BXL Belgium
CORe Department of Medicine University of Melbourne Melbourne 3050 Australia
CSSS Saint Jérôme Saint Jérôme QC J7Z 0H6 Canada
Department of Biomedical and Neuromotor Sciences University of Bologna Bologna Italy
Department of Clinical Neurosciences University of Cambridge Cambridge CB2 0QQ UK
Department of General Medicine Parma University Hospital Parma 43126 Italy
Department of Medicine and Surgery University of Parma Parma 43126 Italy
Department of Neurology Austin Health Heidlberg 3084 Australia
Department of Neurology Box Hill Hospital Monash University Melbourne 3128 Australia
Department of Neurology Faculty of Medicine University of Debrecen Debrecen 4032 Hungary
Department of Neurology John Hunter Hospital Hunter New England Health Newcastle 2305 Australia
Department of Neurology Razi Hospital 2010 Tunis Manouba Tunisia
Department of Neurology The Alfred Hospital Melbourne 3004 Australia
Department of Neuroscience Azienda Ospedaliera Universitaria Modena 41100 Italy
Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio 66100 Chieti Italy
Dokuz Eylul University Konak Izmir 35220 Turkey
Faculty of Medicine and Dental Health Sciences University of Melbourne Melbourne 3050 Australia
Flinders University Adelaide 5042 Australia
GF Ingrassia Department University of Catania Catania 95123 Italy
Haydarpasa Numune Training and Research Hospital Selimiye Mahallesi Istanbul 34668 Turkey
Hospital Universitario Reina Sofia Cordoba 14004 Cordoba Spain
Hospital Universitario Virgen Macarena Sevilla 41009 Spain
IRCCS Mondino Foundation Pavia 27100 Italy
KTU Medical Faculty Farabi Hospital Karadeniz Technical University Trabzon 61080 Turkey
Medical Faculty 19 Mayis University Kurupelit Samsun 55160 Turkey
Melbourne MS Centre Department of Neurology Royal Melbourne Hospital Melbourne 3050 Australia
Policlinico G Rodolico 95123 Catania Italy
Rehabilitation and MS Centre Overpelt and Hasselt University Hasselt 3900 Belgium
Rennes University EHESP REPERES EA 7449 Rennes France
Royal Brisbane and Women's Hospital Herston 4029 Australia
School of Medicine and Public Health University Newcastle 2308 Australia
University of Lyon Claude Bernard University Lyon 1 F 69000 Lyon France
University of Queensland St Lucia 4072 Australia
UOC Neurologia Azienda Sanitaria Unica Regionale Marche AV3 Macerata 62100 Italy
Zuyderland Ziekenhuis Sittard Sittard 6131 BK The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012180
- 003
- CZ-PrNML
- 005
- 20210507101812.0
- 007
- ta
- 008
- 210420s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/brain/awaa231 $2 doi
- 035 __
- $a (PubMed)32947619
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Roos, Izanne $u CORe, Department of Medicine, University of Melbourne, Melbourne, 3050, Australia $u Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, 3050, Australia
- 245 10
- $a Delay from treatment start to full effect of immunotherapies for multiple sclerosis / $c I. Roos, E. Leray, F. Frascoli, R. Casey, JWL. Brown, D. Horakova, EK. Havrdova, M. Trojano, F. Patti, G. Izquierdo, S. Eichau, M. Onofrj, A. Lugaresi, A. Prat, M. Girard, P. Grammond, P. Sola, D. Ferraro, S. Ozakbas, R. Bergamaschi, MJ. Sá, E. Cartechini, C. Boz, F. Granella, R. Hupperts, M. Terzi, J. Lechner-Scott, D. Spitaleri, V. Van Pesch, A. Soysal, J. Olascoaga, J. Prevost, E. Aguera-Morales, M. Slee, T. Csepany, R. Turkoglu, Y. Sidhom, R. Gouider, B. Van Wijmeersch, P. McCombe, R. Macdonell, A. Coles, CB. Malpas, H. Butzkueven, S. Vukusic, T. Kalincik, MSBase, OFSEP investigators
- 520 9_
- $a In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments ('therapeutic lag') on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and yearly review were included in the analysis. For analysis of disability progression, all events in the subsequent 5-year period were included. Density curves, representing incidence of relapses and 6-month confirmed progression events, were separately constructed for each sufficiently represented therapy. Monte Carlo simulations were performed to identify the first local minimum of the first derivative after treatment start; this point represented the point of stabilization of treatment effect, after the maximum treatment effect was observed. The method was developed in a discovery cohort (MSBase), and externally validated in a separate, non-overlapping cohort (OFSEP). A merged MSBase-OFSEP cohort was used for all subsequent analyses. Annualized relapse rates were compared in the time before treatment start and after the stabilization of treatment effect following commencement of each therapy. We identified 11 180 eligible treatment epochs for analysis of relapses and 4088 treatment epochs for disability progression. External validation was performed in four therapies, with no significant difference in the bootstrapped mean differences in therapeutic lag duration between registries. The duration of therapeutic lag for relapses was calculated for 10 therapies and ranged between 12 and 30 weeks. The duration of therapeutic lag for disability progression was calculated for seven therapies and ranged between 30 and 70 weeks. Significant differences in the pre- versus post-treatment annualized relapse rate were present for all therapies apart from intramuscular interferon beta-1a. In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progression in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience early on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kohortové studie $7 D015331
- 650 12
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x aplikace a dávkování $7 D007155
- 650 _2
- $a imunosupresiva $x aplikace a dávkování $7 D007166
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a roztroušená skleróza $x diagnostické zobrazování $x farmakoterapie $x patofyziologie $7 D009103
- 650 _2
- $a natalizumab $x aplikace a dávkování $7 D000069442
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Leray, Emmanuelle $u Rennes University, EHESP, REPERES (Pharmaco-epidemiology and Health services research) - EA 7449, Rennes, France
- 700 1_
- $a Frascoli, Federico $u Faculty of Science, Engineering and Technology, School of Science, Department of Mathematics, Swinburne University of Technology, Melbourne, 3122, Australia
- 700 1_
- $a Casey, Romain $u University of Lyon, Claude Bernard University Lyon 1, F-69000 Lyon, France $u Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, F-69677 Bron, France $u Observatoire Français de la Sclérose en Plaques, Lyon Neuroscience Research Centre, INSERM 1028 et CNRS UMR 5292, F-69003 Lyon, France $u EUGENE DEVIC EDMUS Foundation against multiple sclerosis, state-approved foundation, F-69677 Bron, France
- 700 1_
- $a Brown, J William L $u Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, 12808, Czech Republic
- 700 1_
- $a Havrdova, Eva K $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, 12808, Czech Republic
- 700 1_
- $a Trojano, Maria $u Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, 70122, Italy
- 700 1_
- $a Patti, Francesco $u GF Ingrassia Department, University of Catania, Catania, 95123, Italy $u Policlinico G Rodolico, 95123, Catania, Italy
- 700 1_
- $a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain
- 700 1_
- $a Eichau, Sara $u Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain
- 700 1_
- $a Onofrj, Marco $u Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, 66100 Chieti, Italy
- 700 1_
- $a Lugaresi, Alessandra $u IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, 40139, Italy $u Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
- 700 1_
- $a Prat, Alexandre $u CHUM MS Center and Universite de Montreal, Montreal, H2L 4M1, Canada
- 700 1_
- $a Girard, Marc $u CHUM MS Center and Universite de Montreal, Montreal, H2L 4M1, Canada
- 700 1_
- $a Grammond, Pierre $u CISSS Chaudière-Appalache, Lévis, Levis, G6X 0A1, Canada
- 700 1_
- $a Sola, Patrizia $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, 41100, Italy
- 700 1_
- $a Ferraro, Diana $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, 41100, Italy
- 700 1_
- $a Ozakbas, Serkan $u Dokuz Eylul University, Konak/Izmir, 35220, Turkey
- 700 1_
- $a Bergamaschi, Roberto $u IRCCS Mondino Foundation, Pavia, 27100, Italy
- 700 1_
- $a Sá, Maria José $u Centro Hospitalar Universitário de São João and Universidade Fernando Pessoa, 4249-004 Porto, Portugal
- 700 1_
- $a Cartechini, Elisabetta $u UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, 62100, Italy
- 700 1_
- $a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Karadeniz Technical University, Trabzon, 61080, Turkey
- 700 1_
- $a Granella, Franco $u Department of Medicine and Surgery, University of Parma, Parma, 43126, Italy $u Department of General Medicine, Parma University Hospital, Parma, 43126, Italy
- 700 1_
- $a Hupperts, Raymond $u Zuyderland Ziekenhuis, Sittard, Sittard, 6131 BK, The Netherlands
- 700 1_
- $a Terzi, Murat $u Medical Faculty, 19 Mayis University, Kurupelit, Samsun, 55160, Turkey
- 700 1_
- $a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University Newcastle, 2308, Australia $u Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, 2305, Australia
- 700 1_
- $a Spitaleri, Daniele $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Contrada Amoretta, Avellino, 83100, Italy
- 700 1_
- $a Van Pesch, Vincent $u Cliniques universitaires Saint-Luc, Brussels, 1200 BXL, Belgium
- 700 1_
- $a Soysal, Aysun $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, 34142, Turkey
- 700 1_
- $a Olascoaga, Javier $u Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San San Sebastián, Spain, 20014, Spain
- 700 1_
- $a Prevost, Julie $u CSSS Saint-Jérôme, Saint-Jérôme, QC J7Z 0H6, Canada
- 700 1_
- $a Aguera-Morales, Eduardo $u Hospital Universitario Reina Sofia Cordoba (IMIBIC), 14004 Cordoba, Spain
- 700 1_
- $a Slee, Mark $u Flinders University, Adelaide, 5042, Australia
- 700 1_
- $a Csepany, Tunde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary
- 700 1_
- $a Turkoglu, Recai $u Haydarpasa Numune Training and Research Hospital, Selimiye Mahallesi, Istanbul, 34668, Turkey
- 700 1_
- $a Sidhom, Youssef $u Department of Neurology, Razi Hospital, 2010, Tunis, Manouba, Tunisia
- 700 1_
- $a Gouider, Riadh $u Department of Neurology, Razi Hospital, 2010, Tunis, Manouba, Tunisia
- 700 1_
- $a Van Wijmeersch, Bart $u Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, 3900, Belgium
- 700 1_
- $a McCombe, Pamela $u University of Queensland, St Lucia, 4072, Australia $u Royal Brisbane and Women's Hospital, Herston, 4029, Australia
- 700 1_
- $a Macdonell, Richard $u Department of Neurology, Austin Health, Heidlberg, 3084, Australia $u Faculty of Medicine and Dental Health Sciences, University of Melbourne, Melbourne, 3050, Australia
- 700 1_
- $a Coles, Alasdair $u Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK
- 700 1_
- $a Malpas, Charles B $u CORe, Department of Medicine, University of Melbourne, Melbourne, 3050, Australia $u Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, 3050, Australia
- 700 1_
- $a Butzkueven, Helmut $u Central Clinical School, Monash University, Melbourne, 3004, Australia $u Department of Neurology, The Alfred Hospital, Melbourne, 3004, Australia $u Department of Neurology, Box Hill Hospital, Monash University, Melbourne, 3128, Australia
- 700 1_
- $a Vukusic, Sandra $u University of Lyon, Claude Bernard University Lyon 1, F-69000 Lyon, France $u Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, F-69677 Bron, France $u Observatoire Français de la Sclérose en Plaques, Lyon Neuroscience Research Centre, INSERM 1028 et CNRS UMR 5292, F-69003 Lyon, France
- 700 1_
- $a Kalincik, Tomas $u CORe, Department of Medicine, University of Melbourne, Melbourne, 3050, Australia $u Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, 3050, Australia
- 710 2_
- $a MSBase
- 710 2_
- $a OFSEP investigators
- 773 0_
- $w MED00009356 $t Brain : a journal of neurology $x 1460-2156 $g Roč. 143, č. 9 (2020), s. 2742-2756
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32947619 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101812 $b ABA008
- 999 __
- $a ok $b bmc $g 1650536 $s 1132559
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 143 $c 9 $d 2742-2756 $e 20200901 $i 1460-2156 $m Brain $n Brain $x MED00009356
- LZP __
- $a Pubmed-20210420
